Investigational drug · Phase 2
CPK850
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Retinitis Pigmentosa.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 11, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "CPK850"
First trial start
2018
Aug 22, 2018
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CPK850", any sponsor or status.
Conditions studied
As listed on its trial records.
- Retinitis Pigmentosa
Approved drugs for the same conditions: Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "CPK850" as an intervention, largest first.
- A First-in-human, Proof of Concept Study of CPK850 in Patients With RLBP1 Retinitis PigmentosaCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT03374657 · 12 participants · Start Aug 22, 2018 · Primary completion May 12, 2026
Drug: CPK850 · For: Retinitis Pigmentosa
Sites: Stockholm, Sweden
Newest research
PubMed records naming it or its code names, newest first.
- Nonclinical Safety Evaluation of scAAV8-RLBP1 for Treatment of RLBP1 Retinitis Pigmentosa.
MacLachlan TK, Milton MN, Turner O, et al. · Mol Ther Methods Clin Dev 2018
Also in development for Retinitis Pigmentosa
- BS01Phase 22 trials
Bionic Sight LLC · Retinitis Pigmentosa, Geographic Atrophy (GA) Secondary to Dry Age-related Macular Degeneration (AMD)
- famzeretcelhuman retinal progenitor cells, jCellPhase 21 trial
jCyte, Inc · Retinitis Pigmentosa
- KIO-301Phase 21 trial
Kiora Pharmaceuticals, Inc. · Retinitis Pigmentosa
- OCU400Phase 21 trial
Ocugen · Retinitis Pigmentosa, Leber Congenital Amaurosis
- SPVN06Phase 21 trial
SparingVision · Retinitis Pigmentosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Novartis.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.